QI
LAB icon

QS Investors’s Standard BioTools LAB Stock Holding History

QS Investors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-64,100
Closed -$290K – 1171
2021
Q1 		$290K Hold
64,100
– – ﹤0.01% 997
2020
Q4 		$385K Buy
64,100
+34,100
+114% +$224K ﹤0.01% 901
2020
Q3 		$223K Sell
30,000
-129,700
-81% -$895K ﹤0.01% 1043
2020
Q2 		$641K Sell
159,700
-1,500
-0.9% -$5.22K 0.01% 843
2020
Q1 		$410K Hold
161,200
– – 0.01% 892
2019
Q4 		$563K Sell
161,200
-1,100
-0.7% -$3.87K 0.01% 906
2019
Q3 		$752K Hold
162,300
– – 0.01% 849
2019
Q2 		$2M Buy
+162,300
New +$2.07M 0.02% 587
2016
Q4 		– Sell
-41
Closed -$1K – 1944
2016
Q3 		$1K Buy
41
+12
+41% +$110 ﹤0.01% 1633
2016
Q2 		$1K Buy
+29
New +$273 ﹤0.01% 1674
2016
Q1 		– Sell
-28
Closed -$1K – 2020
2015
Q4 		$1K Buy
+28
New +$275 ﹤0.01% 1694

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

QS Investors's LAB Position: Q2 2021 in Review

QS Investors sold out of Standard BioTools (LAB) in Q2 2021, closing a stake of 64,100 shares — an estimated $290K sold.

QS Investors first reported a position in LAB in Q4 2015 and held it in 11 quarters. The position peaked at $2M in Q2 2019. 113 funds tracked by Wall St. Rank hold LAB as of Q2 2021.

  • QS Investors reported no remaining Standard BioTools position as of Q2 2021 after selling out during the quarter.
  • QS Investors sold 64,100 Standard BioTools shares in Q2 2021, an estimated $290K.
  • QS Investors first reported a position in Standard BioTools in Q4 2015 and held it in 11 quarters.
  • QS Investors's Standard BioTools position peaked at $2M in Q2 2019.
  • 113 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.